Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate-amodiaquine and Dihydroartemisinin-piperaquine in Uncomplicated Falciparum Malaria
NCT03431714Phase 4Completed
- Sponsor
- National Institute for Medical Research
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artesunate + amodiaquine and dihydroartemisinin + piperaquine in Falciparum malaria (PF), sponsored by National Institute for Medical Research. Primary endpoint: Adequate clinical response at 28 days. Started Jul 2017; status: completed.
02
Drugs
artesunate + amodiaquinedihydroartemisinin + piperaquine
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT03431714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431714.